CMMB: AI 评分 49/100 — AI 分析 (4月 2026)

Chemomab Therapeutics Ltd. is a clinical-stage biotech company focused on developing therapeutics for inflammation and fibrosis. Their lead product candidate, CM-101, targets CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Chemomab Therapeutics Ltd., an Israeli clinical-stage biotech firm, specializes in developing CM-101, a humanized monoclonal antibody targeting CCL24 to treat fibrotic and inflammatory diseases like PSC and SSc. With a market cap of $0.01B, the company operates in a competitive biotechnology landscape.

CMMB是做什么的？

Chemomab Therapeutics Ltd., established in 2011 and based in Tel Aviv, Israel, is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapeutics for the treatment of inflammatory and fibrotic diseases. Originally incorporated as Anchiano Therapeutics Ltd., the company rebranded to Chemomab Therapeutics Ltd. in March 2021, marking a strategic shift in its therapeutic focus. The company's primary focus is on CM-101, a humanized monoclonal antibody that inhibits the activity of CCL24, a soluble chemokine implicated in the pathogenesis of several fibrotic and inflammatory conditions. CM-101 is currently under clinical investigation for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), both of which represent significant unmet medical needs. The company is conducting clinical trials to evaluate the safety and efficacy of CM-101 in these indications. Chemomab operates with a team of 20 employees, focusing on research, development, and clinical advancement of its lead candidate.

CMMB的投资论点是什么？

Chemomab Therapeutics' investment thesis hinges on the successful clinical development and commercialization of CM-101. The company's focus on CCL24 inhibition as a therapeutic strategy for fibrotic and inflammatory diseases presents a targeted approach. Key value drivers include positive clinical trial outcomes for CM-101 in PSC and SSc, potential regulatory approvals, and subsequent market penetration. The company's small market capitalization ($0.01B) suggests potential for significant upside if CM-101 achieves clinical and commercial success. Upcoming clinical trial data releases will be critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from other therapies in development.

CMMB在哪个行业运营？

Chemomab Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for therapies targeting fibrotic and inflammatory diseases is substantial, driven by the increasing prevalence of these conditions and the unmet need for effective treatments. Chemomab's focus on CCL24 inhibition differentiates it from competitors pursuing other therapeutic targets. Companies like CANF and GLMD are also developing therapies in related areas, creating a dynamic competitive landscape. The biotechnology industry is experiencing ongoing growth, fueled by technological advancements and increasing investment in healthcare innovation.

Biotechnology

Healthcare

CMMB有哪些增长机遇？

Successful Clinical Trials: Positive results from ongoing and future clinical trials of CM-101 in PSC and SSc are crucial for driving growth. Success in Phase 2 and Phase 3 trials could lead to regulatory approvals and subsequent commercialization. The market for PSC and SSc therapies is estimated to reach billions of dollars, offering significant revenue potential for Chemomab. The timeline for potential FDA approval is estimated to be within the next 3-5 years, contingent on trial outcomes.
Expansion to Additional Indications: Chemomab could expand the development of CM-101 to other fibrotic and inflammatory diseases beyond PSC and SSc. CCL24 is implicated in various conditions, including liver fibrosis and pulmonary fibrosis. Expanding the therapeutic applications of CM-101 could significantly broaden the company's market opportunity. This expansion could begin within the next 2-3 years, following further clinical data and strategic decisions.
Strategic Partnerships and Licensing Agreements: Chemomab could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of CM-101. Licensing agreements could provide upfront payments, milestone payments, and royalties on future sales. Such partnerships could provide financial resources and expertise to support the company's growth. These partnerships could materialize within the next 1-2 years, depending on clinical progress and partnering opportunities.
Orphan Drug Designation and Regulatory Exclusivity: Obtaining orphan drug designation for CM-101 in PSC and SSc could provide regulatory exclusivity and market protection. Orphan drug designation provides incentives such as tax credits, reduced regulatory fees, and market exclusivity for a period of 7 years in the US and 10 years in Europe. This exclusivity could enhance the commercial value of CM-101. The company has already pursued orphan drug designation, and potential approvals could be granted within the next year.
Advancements in Manufacturing and Formulation: Improving the manufacturing process and formulation of CM-101 could reduce production costs and enhance its efficacy and safety profile. These advancements could improve the drug's competitive position and market acceptance. Investing in these improvements could lead to long-term cost savings and increased profitability. These advancements are ongoing and could yield results within the next 1-2 years.

Chemomab's lead product candidate, CM-101, is a humanized monoclonal antibody targeting CCL24, a chemokine involved in fibrosis and inflammation.
The company is focused on developing CM-101 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Chemomab has a small team of 20 employees, reflecting its clinical-stage focus and limited commercial operations.
The company's market capitalization is $0.01B, indicating its early stage and potential for growth.
Chemomab's P/E ratio is -1.23, reflecting its current lack of profitability as it invests in research and development.

CMMB提供哪些产品和服务？

Discovers and develops therapeutics for inflammation and fibrosis.
Focuses on CM-101, a humanized monoclonal antibody.
Targets soluble chemokine CCL24.
Develops treatments for primary sclerosing cholangitis (PSC).
Develops treatments for systemic sclerosis (SSc).
Conducts clinical trials to evaluate CM-101's safety and efficacy.

CMMB如何赚钱？

Develops and patents novel therapeutic antibodies.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approvals from agencies like the FDA and EMA.
Potentially commercializes products directly or through partnerships.
Generates revenue through product sales, licensing agreements, and milestone payments.

Patients suffering from primary sclerosing cholangitis (PSC).
Patients suffering from systemic sclerosis (SSc).
Healthcare providers who prescribe and administer treatments.
Pharmaceutical companies that may partner or acquire Chemomab.
Clinical trial participants who contribute to drug development.

Patent protection for CM-101 and related technologies.
Proprietary knowledge and expertise in CCL24 inhibition.
Clinical data demonstrating the efficacy and safety of CM-101.
Orphan drug designation providing market exclusivity.
Established relationships with key opinion leaders and clinical investigators.

什么因素可能推动CMMB股价上涨？

Upcoming: Data readout from ongoing Phase 2 clinical trial of CM-101 in primary sclerosing cholangitis (PSC) - expected Q4 2026.
Upcoming: Initiation of Phase 2 clinical trial of CM-101 in systemic sclerosis (SSc) - expected Q3 2026.
Ongoing: Potential for strategic partnerships and licensing agreements with larger pharmaceutical companies.
Ongoing: Pursuit of orphan drug designation for CM-101 in additional indications.

CMMB的主要风险是什么？

Potential: Clinical trial failures for CM-101 in PSC and SSc.
Potential: Regulatory hurdles and delays in obtaining marketing approvals.
Potential: Competition from other therapies in development for fibrotic and inflammatory diseases.
Potential: Dependence on the success of a single product candidate (CM-101).
Ongoing: Limited financial resources and potential need for additional funding.

CMMB的核心优势是什么？

Novel therapeutic target (CCL24 inhibition).
Lead product candidate (CM-101) in clinical development.
Focus on unmet medical needs (PSC and SSc).
Experienced management team.

CMMB的劣势是什么？

Limited financial resources.
Small team size.
Dependence on the success of CM-101.
Lack of commercial infrastructure.

CMMB有哪些机遇？

Positive clinical trial results.
Regulatory approvals and market access.
Strategic partnerships and licensing agreements.
Expansion to additional indications.

CMMB面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from other therapies.
Patent expiration.

CMMB的竞争对手是谁？

BioVie Inc. — Developing therapies for liver diseases. — (BIVI)
Can-Fite BioPharma Ltd — Developing therapies for inflammatory and liver diseases. — (CANF)
Cero Therapeutics, Inc. — Focusing on cancer immunotherapy. — (CERO)
Elabscience Biotechnology Inc. — Provides research reagents and services. — (ELAB)
Galmed Pharmaceuticals Ltd. — Developing therapies for liver diseases. — (GLMD)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Adi Mor George
Headquarters: Tel Aviv, IL
Employees: 20
Founded: 2019

AI Insight

AI analysis pending for CMMB

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Chemomab Therapeutics Ltd. do?

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of inflammatory and fibrotic diseases. Its lead product candidate, CM-101, is a humanized monoclonal antibody that targets CCL24, a chemokine involved in the pathogenesis of these diseases. The company is currently conducting clinical trials to evaluate CM-101's safety and efficacy in patients with primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab aims to address unmet medical needs in these areas by developing targeted therapies that can improve patient outcomes.

What do analysts say about CMMB stock?

Analyst coverage of CMMB is currently limited, reflecting its small market capitalization and early stage of development. Key valuation metrics include the potential peak sales of CM-101 in PSC and SSc, the probability of clinical trial success, and the discount rate applied to future cash flows. Growth considerations include the potential for label expansion to additional indications and the ability to secure strategic partnerships. Analyst opinions will likely be heavily influenced by upcoming clinical trial data releases.

What are the main risks for CMMB?

The main risks for Chemomab Therapeutics include clinical trial failures, regulatory hurdles, and competition from other therapies. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory approvals are not guaranteed, and delays could push back timelines and increase costs. Competition from larger pharmaceutical companies with more resources could also pose a challenge. Additionally, the company's dependence on a single product candidate (CM-101) increases its vulnerability to setbacks.

How does Chemomab Therapeutics Ltd. manage patent expiration risks?

Chemomab Therapeutics Ltd. manages patent expiration risks through a multi-faceted approach. This includes actively pursuing patent protection for its lead compound CM-101, as well as any novel formulations or methods of use. The company also aims to develop a strong pipeline of follow-on compounds and technologies to mitigate the impact of potential patent expirations. Furthermore, Chemomab continuously monitors the competitive landscape and actively defends its intellectual property rights against infringement.

What revenue streams does Chemomab Therapeutics Ltd. have in healthcare?

As a clinical-stage biotechnology company, Chemomab Therapeutics Ltd. currently does not generate revenue from product sales. Its potential future revenue streams are contingent upon the successful clinical development, regulatory approval, and commercialization of CM-101. Potential revenue streams include direct sales of CM-101 in approved indications, licensing agreements with pharmaceutical companies, and milestone payments related to clinical development and regulatory achievements. The timing and magnitude of these revenue streams are uncertain and dependent on various factors.